Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 03, 2017 Filed May 5, 2017 15:58 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 6,365 | $27.58 | $175,546.70 |
DisclosureSEC source: 0001140361-17-018553 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 01, 2017 Filed May 3, 2017 17:25 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,250 | $68.60 | $85,750.00 |
DisclosureSEC source: 0001140361-17-018050 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,783 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. Read SEC document |
| April 24, 2017 Filed Apr 25, 2017 23:16 UTC |
ROBERTS CHRISTOPHER GDirector
|
Exercise / conversionResMed Common Stock Options · Derivative | 28,403 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-016775 · doc1.xml · derivative · entry 7 ROBERTS CHRISTOPHER G · CIK 0001186112 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 28,403 shares Expires 2018-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction approved to exercise options and hold shares acquired through purchase. F2 · derivative.exercise_date: Options vest in full on (i) the first November 11 following the grant date, or (ii) the first annual shareholder's meeting following grant date. Read SEC document |
| April 24, 2017 Filed Apr 25, 2017 23:16 UTC |
ROBERTS CHRISTOPHER GDirector
|
Exercise / conversionResMed Common Stock Options · Derivative | 24,390 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-17-016775 · doc1.xml · derivative · entry 6 ROBERTS CHRISTOPHER G · CIK 0001186112 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 24,390 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction approved to exercise options and hold shares acquired through purchase. F2 · derivative.exercise_date: Options vest in full on (i) the first November 11 following the grant date, or (ii) the first annual shareholder's meeting following grant date. Read SEC document |
| April 24, 2017 Filed Apr 25, 2017 23:16 UTC |
ROBERTS CHRISTOPHER GDirector
|
Exercise / conversionResMed Common Stock | 28,403 | $27.58 | $783,354.74 |
DisclosureSEC source: 0001140361-17-016775 · doc1.xml · nonDerivative · entry 2 ROBERTS CHRISTOPHER G · CIK 0001186112 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction approved to exercise options and hold shares acquired through purchase. Read SEC document |
| April 24, 2017 Filed Apr 25, 2017 23:16 UTC |
ROBERTS CHRISTOPHER GDirector
|
Exercise / conversionResMed Common Stock | 24,390 | $33.70 | $821,943.00 |
DisclosureSEC source: 0001140361-17-016775 · doc1.xml · nonDerivative · entry 1 ROBERTS CHRISTOPHER G · CIK 0001186112 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction approved to exercise options and hold shares acquired through purchase. Read SEC document |
| April 17, 2017 Filed Apr 18, 2017 18:55 UTC |
Hollingshead JamesPresident, Americas
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,264 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001140361-17-016070 · doc1.xml · derivative · entry 4 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,284 Underlying: ResMed Common Stock · 5,264 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest ? per year. Read SEC document |
| April 17, 2017 Filed Apr 18, 2017 18:55 UTC |
Hollingshead JamesPresident, Americas
|
SaleResMed Common Stock | 1,875 | $68.37 | $128,193.75 |
DisclosureSEC source: 0001140361-17-016070 · doc1.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,795 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| April 17, 2017 Filed Apr 18, 2017 18:55 UTC |
Hollingshead JamesPresident, Americas
|
SaleResMed Common Stock | 5,264 | $68.37 | $359,899.68 |
DisclosureSEC source: 0001140361-17-016070 · doc1.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,670 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| April 17, 2017 Filed Apr 18, 2017 18:55 UTC |
Hollingshead JamesPresident, Americas
|
Exercise / conversionResMed Common Stock | 5,264 | $43.63 | $229,668.32 |
DisclosureSEC source: 0001140361-17-016070 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| April 04, 2017 Filed Apr 6, 2017 17:14 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-015102 · doc1.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,460 Underlying: ResMed Common Stock · 20,000 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| April 04, 2017 Filed Apr 6, 2017 17:14 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 20,000 | $70.67 | $1,413,360.00 |
DisclosureSEC source: 0001140361-17-015102 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,557 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 70.42 to 71.14. The price reported above represents the weighted average sales price. Read SEC document |
| April 04, 2017 Filed Apr 6, 2017 17:14 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 20,000 | $27.58 | $551,600.00 |
DisclosureSEC source: 0001140361-17-015102 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 23:52 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,250 | $71.65 | $89,562.50 |
DisclosureSEC source: 0001140361-17-014718 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,033 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 21:58 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,365 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-014690 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,550 Underlying: ResMed Common Stock · 6,365 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 21:58 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 6,365 | $71.59 | $455,644.89 |
DisclosureSEC source: 0001140361-17-014690 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,896 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.57 to $71.65. The price reported above reflects the weighted average sale price. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 21:58 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 6,365 | $27.58 | $175,546.70 |
DisclosureSEC source: 0001140361-17-014690 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 20:51 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 3,915 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-010999 · doc1.xml · derivative · entry 5 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,460 Underlying: ResMed Common Stock · 3,915 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 20:51 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 16,085 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-17-010999 · doc1.xml · derivative · entry 4 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 16,085 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 20:51 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 20,000 | $71.70 | $1,434,000.00 |
DisclosureSEC source: 0001140361-17-010999 · doc1.xml · nonDerivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,557 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 71.48 to 71.97. The price reported above represents the weighted average sales price. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 20:51 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 3,915 | $27.58 | $107,975.70 |
DisclosureSEC source: 0001140361-17-010999 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 20:51 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 16,085 | $33.70 | $542,064.50 |
DisclosureSEC source: 0001140361-17-010999 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 21:02 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,365 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-010699 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,915 Underlying: ResMed Common Stock · 6,365 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 21:02 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 6,365 | $72.22 | $459,680.30 |
DisclosureSEC source: 0001140361-17-010699 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,896 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 21:02 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 6,365 | $27.58 | $175,546.70 |
DisclosureSEC source: 0001140361-17-010699 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 02:57 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,250 | $72.48 | $90,600.00 |
DisclosureSEC source: 0001140361-17-010395 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,283 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:36 UTC |
WAREHAM JOHN PDirector
|
Exercise / conversionResMed Common Stock Options · Derivative | 28,403 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-009665 · doc1.xml · derivative · entry 3 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Commmon Stock · 28,403 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:36 UTC |
WAREHAM JOHN PDirector
|
SaleResMed Common Stock | 28,403 | $71.77 | $2,038,454.91 |
DisclosureSEC source: 0001140361-17-009665 · doc1.xml · nonDerivative · entry 2 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $71.64 to $71.91. The price reported above reflects the weighted average sale price. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:36 UTC |
WAREHAM JOHN PDirector
|
Exercise / conversionResMed Common Stock | 28,403 | $27.58 | $783,354.74 |
DisclosureSEC source: 0001140361-17-009665 · doc1.xml · nonDerivative · entry 1 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 20:22 UTC |
ROBERTS CHRISTOPHER GDirector
|
SaleResMed Common Stock | 15,000 | $72.10 | $1,081,500.00 |
DisclosureSEC source: 0001140361-17-009111 · doc1.xml · nonDerivative · entry 2 ROBERTS CHRISTOPHER G · CIK 0001186112 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Cabbit Pty Ltd Disclosed balance after: 298,900 F1 · shares: Trade executed as CDI on Australian Securities Exchange converted at 10:1. F2 · price: ASX sale price average of A$ 9.38 was converted using the foreign exchange rate on the transaction date of 1 AUD to .76862 USD. Trade was executed in multiple trades ranging in from A$ 9.38 to A$ 9.385 or USD 72.09 to 72.14. Read SEC document |
| February 20, 2017 Filed Feb 21, 2017 19:11 UTC |
ROBERTS CHRISTOPHER GDirector
|
SaleResMed Common Stock | 10,000 | $71.91 | $719,100.00 |
DisclosureSEC source: 0001140361-17-008291 · doc1.xml · nonDerivative · entry 2 ROBERTS CHRISTOPHER G · CIK 0001186112 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Cabbit Pty Ltd Disclosed balance after: 313,900 F1 · shares: Trade executed as CDI on Australian Securities Exchange converted at 10:1. F2 · price: ASX sale price average of A$ 9.3715 was converted using the foreign exchange rate on the transaction date of 1 AUD to .76743 USD. Trade was executed in multiple trades ranging in from A$ 9.37 to A$ 9.40 or USD 71.90 to 72.13. Read SEC document |
| February 06, 2017 Filed Feb 7, 2017 20:14 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-17-004829 · doc1.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,085 Underlying: ResMed Common Stock · 20,000 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| February 06, 2017 Filed Feb 7, 2017 20:14 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 20,000 | $68.32 | $1,366,420.00 |
DisclosureSEC source: 0001140361-17-004829 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,557 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 67.58 to 68.58. The price reported above represents the weighted average sales price. Read SEC document |
| February 06, 2017 Filed Feb 7, 2017 20:14 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 20,000 | $33.70 | $674,000.00 |
DisclosureSEC source: 0001140361-17-004829 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 20:22 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,365 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-004529 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,280 Underlying: ResMed Common Stock · 6,365 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 20:22 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 6,365 | $67.16 | $427,473.40 |
DisclosureSEC source: 0001140361-17-004529 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,896 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 20:22 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 6,365 | $27.58 | $175,546.70 |
DisclosureSEC source: 0001140361-17-004529 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 22:22 UTC |
Hollingshead JamesPresident, Americas
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,264 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001140361-17-002310 · doc1.xml · derivative · entry 4 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,548 Underlying: ResMed Common Stock · 5,264 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest ? per year. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 22:22 UTC |
Hollingshead JamesPresident, Americas
|
SaleResMed Common Stock | 1,820 | $64.44 | $117,280.80 |
DisclosureSEC source: 0001140361-17-002310 · doc1.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,670 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 22:22 UTC |
Hollingshead JamesPresident, Americas
|
SaleResMed Common Stock | 5,264 | $64.44 | $339,212.16 |
DisclosureSEC source: 0001140361-17-002310 · doc1.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,490 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 22:22 UTC |
Hollingshead JamesPresident, Americas
|
Exercise / conversionResMed Common Stock | 5,264 | $43.63 | $229,668.32 |
DisclosureSEC source: 0001140361-17-002310 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| January 04, 2017 Filed Jan 5, 2017 22:24 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-17-000783 · doc1.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,085 Underlying: ResMed Common Stock · 20,000 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| January 04, 2017 Filed Jan 5, 2017 22:24 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 20,000 | $62.14 | $1,242,760.00 |
DisclosureSEC source: 0001140361-17-000783 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,557 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 61.72 to 62.30. The price reported above represents the weighted average sales price. Read SEC document |
| January 04, 2017 Filed Jan 5, 2017 22:24 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 20,000 | $33.70 | $674,000.00 |
DisclosureSEC source: 0001140361-17-000783 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:01 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,365 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-000356 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,645 Underlying: ResMed Common Stock · 6,365 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:01 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 6,365 | $61.95 | $394,311.75 |
DisclosureSEC source: 0001140361-17-000356 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,896 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:01 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 6,365 | $27.58 | $175,546.70 |
DisclosureSEC source: 0001140361-17-000356 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 23, 2016 Filed Dec 27, 2016 20:27 UTC |
FARRELL PETER CDirector
|
GiftResMed Common Stock | 9,850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-16-090788 · doc1.xml · nonDerivative · entry 4 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,557 F4 · kind: Represents a gift of shares to the Greater Houston Community Foundation. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F4 · price: Represents a gift of shares to the Greater Houston Community Foundation. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| December 23, 2016 Filed Dec 27, 2016 20:27 UTC |
FARRELL PETER CDirector
|
GiftResMed Common Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-16-090788 · doc1.xml · nonDerivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,407 F3 · kind: Represents a gift of shares to the University of San Diego. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F3 · price: Represents a gift of shares to the University of San Diego. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| December 22, 2016 Filed Dec 27, 2016 20:27 UTC |
FARRELL PETER CDirector
|
GiftResMed Common Stock | 2,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-16-090788 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,907 F2 · kind: Represents a gift of shares to Donors Trust, Inc. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F2 · price: Represents a gift of shares to Donors Trust, Inc. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.